the latest year for which mortality statistics are available, and it accounts for 17% of all new cases registered and 25% of all deaths due to cancer.
This high incidence is of course not limited to the UK. Thus in the USA there are in excess of 100,000 deaths annually (Brown & Kessler, 1988) . Worldwide, over the past 20 years there has been a continuing increase in lung cancer mortality (Parkin, 1989) . Death rates from lung cancer have more than doubled in women in many developed countries and are likely to exceed those from breast cancer (Stanley & Stjernsward, 1989) .
Two papers published in this issue of the British Journal of Cancer are of interest in the context of the overall national incidence and mortality figures (Connolly et al., 1990; Watkin et al., 1990 ). They address not only these two general parameters as seen in two well documented regional cancer registries (Yorkshire and Mersey), but also attempt to relate them to methods of treatment and the changes seen over recent years.
The third paper is a salutary warning against undue optimism with respect to improvements in survival in small cell-lung cancer (SCLC). This paper from the UK Cancer Coordinating Committee for Research-Lung Cancer Subcommittee (UKCCCR-LCS), demonstrates that long-term survival, even for SCLC patients treated in a clinical trial context, still remains dismal in spite of improvements over the past 20 years (Souhami & Law, 1990) .
The two regional registry series, although presented somewhat differently, lead to remarkably similar conclusions. It should be noted that one of the databases records all those cases registered during life (Yorkshire, YCRO), while the other (Mersey) encompasses all cases, including those diagnosed and registered at death. This underestimates the total YCRO registration by less than 10% but will have an impact on the total denominator of cases analysed for individual treatment strategies. Histological classifications and treatment descriptions are also only generally comparable.
The overall incidence did not change much over their respective study periods (1976 ( -1983 ( for YCRO and 1974 ( -1986 for Mersey). However, the increase in proportion for females registered is in accord with recent national and international trends (Stanley & Stjernsward, 1989 Observations about changes in regional survival results in the context of these new complete denominators are noteworthy. Not surprisingly treated patients live longer than untreated ones, but 17% of untreated squamous carcinoma patients were alive at 1 year (Mersey) or around 5% untreated alive at 2 years (YCRO). These were presumably the patients deemed of poorest prognosis at diagnosis. Such data need to be remembered in assessing the value of palliative treatments.
Clinical practice for NSCLC has essentially remained unchanged over the study period. The trend towards more surgery in patients aged over 70, and improved survival in that age group is noted in the YCRO study. This is thought to relate to improvements in surgical practice. While radiotherapy and chemotherapy have largely retained their palliative role in NSCLC in the above two series, improvements in radical radiotherapy techniques (e.g. by CHART; Dische & Saunders, 1989) or chemotherapy (e.g. Gralla & Kris, 1988) may modify this position in the future.
The treatment of SCLC remains one of more promise than fulfilment. Thus a large specialist centre has recently reported 5-year survival of 2.5% following treatment (Osterlind et al., 1988 ). This is not very different from those of 3.5% for Mersey and of about 3.7% in the UKCCCR-LCS series. These poor long-term results are seen in spite of some improvements in the median and 2-year survival times over the study period. The increasing impact of chemotherapy is deemed to be responsible for the improvements. In the regional studies participation in multicentre trials such as those conducted by the MRC have had both an educational effect on clinical practice and a beneficial effect on short-term survival parameters.
Questions on the role of surgery and chemotherapy in SCLC have also been addressed. Surgery was reported as being of less value than radiotherapy for limited disease SCLC in an early MRC trial (Medical Research Council, 1966) . However, subsequent improvements in chemotherapy have raised questions about the role of radiotherapy and revised views about the role of surgery. Several reports have now demonstrated 5-year survivals for surgically treated SCLC of greater than 10% (Shields, 1986) . These are well in excess of the 2.5-3.7% reported in the UKCCCR-LCSC. In the Mersey study 5-year survival results for surgical cases were 10% overall and 22.5% following lobectomy. In the YCRO series a 2-year survival of 11% is reported. What is particularly useful about these two reports is that these survivals can now be placed in the perspective of the total denominator. In Merseyside 11% and in the YCRO series 6% of all registered SCLC underwent surgical resection. It is also not clear how much was chemotherapy added to the surgery to influence these results. In this context it should be noted that 72/225 (32%) received both modalities in the Mersey series. The impact of surgery alone as a treatment modality for SCLC is therefore only a small one in the overall incidence of that disease.
The question as to whether or not thoracic radiotherapy improves results in limited disease remains an open one. The role of radiotherapy is SCLC is overviewed in the UKC-CCR-LSC study. It fails to demonstrate any difference in the per cent of long-term survivors whether or not radiotherapy was given. However, it is not a true metanalysis as only one of the studies, which also included extensive disease patients, addressed the question in a randomised way. Many believe that thoracic radiotherapy does reduce local recurrence and significantly increases 2-year survival in limited disease, but few series report survival in large numbers at a later time (reviewed by Bleehen, 1988 al., 1988; Spiegelman et al., 1989) . These can define groups for whom intensive therapy is indicated and others for whom brief courses of palliative care are all that is sensible. Carefully conducted randomised studies will not only help to define better curative treatments but also define the minimal treatment required for palliation. Such studies are now being conducted by groups such as the MRC Lung Cancer Working Party for both SCLC and NCSLC.
Finally, at the risk of being boring one should recognise that lung cancer is a preventable disease. In spite of the welcome recent trend of a small reduction in the male mortality rate, the overall female lung cancer rate is continuing to rise. Anti-smoking programmes such as those being conducted nationally, and the Smoke-free Europe programme jointly adopted by WHO and the 'Europe Against Cancer' of the European Community deserve our active support (WHO, 1987) .
